
The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.
The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.
The newly appointed director for the Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital details his personal responsibilities and the long-term goals for the new center.
Patricia Melville, NP-C, MSCN, and Marijean Buhse, PhD, NP-C, MSCN, present their lecture titled, "Comorbidities and MS: Critical Thinking About DMTs and Vaccines" as part of the 2020 CMSC Virtual Annual Meeting.
Peter Calabresi, MD, delivers the Whitaker Lecture as part of the 2020 CMSC Virtual Annual Meeting.
Amy Sullivan, PsyD, ABPP, presents her lecture titled, "Science, Art, and Practice of Behavioral Medicine" as part of the 2020 CMSC Virtual Annual Meeting.
Brian Weinshenker, MD presents his lecture titled, "Neuromyelitis Optica Spectrum Disorders: Emerging Treatment Options" as part of the 2020 CMSC Virtual Annual Meeting.
Patricia Coyle, MD, delivers her lecture titled, "Progressive MS: Diagnosis, Clinical Course and Long-Term Management" as part of the 2020 CMSC Virtual Annual Meeting.
Evobrutinib, a highly selective BTK inhibitor for the treatment of relapsing multiple sclerosis, showed long-term safety and success in reducing annualized relapse rates.